Diagnostic and therapeutic procedures in chronic pruritus;Diagnostisches und therapeutisches vorgehen bei chronischem pruritus

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 4, 2006, Pages 350-370

  Ständer, Sonja ^a   Streit, Markus ^b   Darsow, Ulf ^c   Niemeier, Volker ^d   Vogelgsang, Maria ^e   Ständer, Hartmut ^a,f   Gieler, Uwe ^d   Gollnick, Harald ^g   Metze, Dieter ^a   Weisshaar, Elke ^h  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e Hautarztpraxis   (Germany)

^f Paulinenkrankenhaus ^*  (Germany)

^g UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPRURITIC AGENT; CALCINEURIN INHIBITOR; CANNABINOID RECEPTOR AGONIST; CAPSAICIN; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN A; DOXEPIN; ERYTHROPOIETIN; GABAPENTIN; GLUCOCORTICOID; HETASTARCH; IMMUNOSUPPRESSIVE AGENT; KETOTIFEN; LIDOCAINE; LOCAL ANESTHETIC AGENT; NALTREXONAZINE; ONDANSETRON; PIMECROLIMUS; RIFAMPICIN; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG;

ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BILIARY CIRRHOSIS; CHRONIC CHOLECYSTITIS; CHRONIC DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; DRUG EFFECT; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; ENDOSCOPY; EPIDEMIOLOGICAL DATA; GENODERMATOSIS; HELICOBACTER INFECTION; HEMATOLOGIC DISEASE; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; INTESTINE INFECTION; LOCAL THERAPY; LYMPHOPROLIFERATIVE DISEASE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOTHERAPY; POLYCYTHEMIA VERA; POPULATION RESEARCH; PRURITUS; PSORIASIS; PSYCHOSOMATIC DISORDER; RENAL REPLACEMENT THERAPY; REVIEW; SKIN DISEASE; SKIN EXAMINATION; SOLID TUMOR; SYMPTOMATOLOGY; SYSTEMIC DISEASE; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TOPICAL TREATMENT; TREATMENT INDICATION; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; GERMANY; PRACTICE GUIDELINE; STANDARD;

ANTIPRURITICS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; GERMANY; HUMANS; PRACTICE GUIDELINES; PRURITUS;

EID: 33646844241     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.05887.x     Document Type: Review

References (194)

1. Rothmann S. Physiology of itching. Physiol Rev 1941; 21: 357-381.
2. Kantor GR, Lookingbill DP. Generalized pruritus and systemic disease. J Am Acad Dermatol 1983; 9: 375-382.
3. Dalgard F, Svensson A, Holm JO, Sundby J. Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. Br J Dermatol 2004; 151: 452-457.
4. Zirwas MJ, Seraly MP. Pruritus of unknown origin: a retrospective study. J Am Acad Dermatol 2001; 45: 892-896.
5. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE. Specific C-receptors for itch in human skin. J Neurosci 1997; 17: 8003-8008.
6. Darsow U, Drzezga A, Frisch M, Munz F, Weilke F, Bartenstein P, Schwaiger M, Ring J. Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol 2000; 115: 1029-1033.
7. 2O positron emission tomography studies. Pain 2001; 92: 295-305.
8. Hsieh JC, Hägermark O, Stahle-Backdahl M, Ericson K, Eriksson L, Stone-Elander S, Ingvar M. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 1994; 72: 3004-3008.
9. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361: 690-694.
10. Ständer S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus - cutaneous elicitation of itch. Arch Dermatol 2003; 139: 1463-1470.
11. Hägermark O, Strandberg K, Hamberg M. Potentiation of itch and flare responses in human skin by prostaglandins E2 and H2 and a prostaglandin endoperoxide analog. J Invest Dermatol 1977; 69: 527-530.
12. Sugiura T, Tominaga M, Katsuya H, Mizumura K. Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J Neurophysiol 2002; 88: 544-548.
13. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, Earley TJ, Dragoni I, McIntyre P, Bevan S, Patapoutian A. A TRP channel that senses cold stimuli and menthol. Cell 2002; 108: 705-715.
14. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, HricikTR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003; 112: 819-829.
15. Ständer S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of m-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 2002; 110: 75-83.
16. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005; 38: 177-188.
17. Bromm B, Scharein E, Darsow U, Ring J. Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett 1995; 187: 157-160.
18. Fjellner B, Arnetz BB, Eneroth P, Kallner A. Pruritus during standardized mental stress. Relationship to psychoneuroendocrine and metabolic parameters. Acta Derm Venereol 1985; 65: 199-205.
19. Fjellner B, Arnetz BB. Psychological predictors of pruritus during mental stress. Acta Derm Venereol 1985; 65: 504-508.
20. Magerl W. Neurophysiologie des Juckens. Allergologie 1991; 14: 395-405.
21. Piercey MF, Dobry PJ, Schröder LA, Einspahr FJ. Behavioral evidence that substance P may be a spinal cord sensory neurotransmitter. Brain Res 1981; 210: 407-412.
22. Handwerker HO. Pathophysiologie des Juckreizes. In: Garbe C, Rassner G: Dermatologie: Leitlinien und Qualitätssicherung für Diagnostik und Therapie. Berlin Heidelberg New York: Springer Verlag, 1998: 43-45.
23. Ikoma A, Rukwied R, Ständer S, Steinhoff M, Miyachi Y, Schmelz M. Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 2003; 139: 1455-1458.
24. Stangier U, Gieler U. Somatoforme Störungen in der Dermatologie. Psychotherapie 1997; 2: 91-101.
25. Gieler U, Niemeier V, Brosig B, Kupfer J. Psychosomatic aspects of pruritus. Dermatol Psychosom 2002; 3: 6-13.
26. Kodama A, Horikawa T, Suzuki T, Ajiki W, Takashima T, Harada S, Ichihashi M. Effect of stress on atopic dermatitis: investigation in patients after the great hanshin earthquake. J Allergy Clin Immunol 1999; 104: 173-176.
27. Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, Johnson EH, Ellis CN, Voorhees JJ. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988; 124: 1052-1057.
28. Niemeier V, Kupfer J, Gieler U. Observations during an itch-inducing lecture. Dermatol Psychosom 2000; 1 (suppl 1): 15-18.
29. Scholz OB, Hermanns N. Krankheitsverhalten und Kognitionen beeinflussen die Juckreiz-Wahrnehmung von Patienten mit atopischer Dermatitis. Z Klin Psychol Psychother 1994; 23: 127-135.
30. Musaph H. Psychogenic Pruritus. Dermatologica 1967; 135: 126-130.
31. Hansen O, Küchler T, Lotz GR, Richter R, Wilckens A. Es juckt mich in den Fingern, aber mir sind die Hände gebunden. Z Psychosom Med Psychoanal 1981; 27: 275-290.
32. Thomä H. Über die Unspezifität psychosomatischer Erkrankungen am Beispiel einer Neurodermitis mit zwanzigjähriger Katamnese. Psyche (Stuttg) 1980; 34: 589-624.
33. Doucet P. Pruritus ani. Int J Psychoanal 1988; 69: 409-417.
34. Gupta MA, Gupta AK. Stressful major life events are associated with a higher frequency of cutaneous sensory symptoms: an empirical study of non-clinical subjects. J Eur Acad Dermatol Venereol 2004; 18: 560-565.
35. Sheehan-Dare RA, Henderson MJ, Cotterill JA. Anxiety and depression in patients with chronic urticaria and generalized pruritus. Br J Dermatol 1990; 123: 769-774.
36. Laurent A, Boucharlat J, Bosson JL, Derry A, Imbert R. Psychological assessment of patients with idiopathic pruritus ani. Psychother Psychosom 1997; 66: 163-166.
37. Calikusu C, Yucel B, Polat A, Baykal C. The relation of psychogenic excoriation with psychiatric disorders: a comparative study. Compr Psychiatry 2003; 44: 256-261.
38. Twycross R, Greaves MW, Handwerker H, Jones AE, Libretto SE, Szepietowski JC, Zylicz Z. Itch: scratching more than the surface. QJM 2003; 96: 7-26.
39. Metze D, Reimann S, Luger TA. Juckreiz -Symptom oder Krankheit. In: Plewig G, Przybilla B: Vorträge und Dia-Klinik der 15. Fortbildungswoche. Fortbildungswoche für Praktische Dermatologie und Venerologie. Serie: Fortschritte der praktischen Dermatologie und Venerologie, 15. Berlin Heidelberg New York: Springer Verlag, 1997: 77-86.
40. Streit M, Braathen L. Pruritus sine materia: Eine Analyse der Untersuchungsdaten von 20 stationär abgeklärten Fällen. Dermatologica helvetica 2001; 5: 38.
41. Zucker I, Yosipovitch G, David M, Gafter U, Boner G. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: Uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003; 49: 842-846.
42. Ghent C. Cholestatic pruritus. In: Bernhard JD: Itch: mechanisms and management of pruritus. New York: Mc Graw-Hill, 1994: 229-242.
43. Diehn F, Tefferi A. Pruritus in polycythaemia vera. Prevalence, laboratory correlates and management. Br J Haematol 2001; 115: 619-621.
44. Egli F, Wieczorek A, Niemöller M, Rhyner K. Polycythaemia vera: Klinik und Verlauf bei 86 Patienten. Schweiz Med Wochenschr 1988; 118: 1969-1975.
45. Brunner W. Pruritus - also a challenge in internal medicine. Schweiz Med Wochenschr 1995; 125: 2244-2250.
46. Goldman B, Koh H. Pruritus and malignancy. In: Bernhard JD: Itch: mechanisms and management of pruritus. New York: McGraw-Hill, 1994: 299-319.
47. Caravati CM Jr, Richardson DR, Wood BT, Cawley EP. Cutaneous manifestations of hyperthyroidism. South Med J 1969; 62: 1127-1130.
48. Ständer S, Weisshaar E, Steinhoff M, Luger TA, Metze D. Pruritus - Pathophysiologie, Klinik und Therapie - Eine Übersicht. J Dtsch Dermatol Ges 2003; 1: 105-118.
49. Bueller HA, Bernhard JD. Review of pruritus therapy. Dermatol Nurs 1998; 10: 101-107.
50. Streit M, von Felbert V, Braathen LR. Pruritus sine materia. Pathophysiologie, Abklärung und Therapie. Hautarzt 2002; 53: 830-849.
51. Weisshaar E, Dunker N, Domröse U, Neumann KH, Gollnick H. Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy. Clin Nephrol 2003; 59: 124-129.
52. Yosipovitch G. Epidemiology of itching in skin and systemic diseases. In: Yosipovitch G, Greaves MW, Fleischer AB, McGlone F: Itch: basic mechanisms and therapy. New York Basel: Marcel Dekker, 2004, 183-191.
53. Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur JC. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain. 2004; 127: 1606-1615.
54. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. Br J Dermatol 1997; 136: 553-559.
55. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980: 92: 44-47.
56. Weisshaar E, Witteler R, Diepgen TL, Luger TA, Ständer S. Pruritus in der Schwangerschaft -eine häufige diagnostische und therapeutische Herausforderung. Hautarzt 2005; 56: 48-57.
57. Schneider G, Gieler U. Die Haut als Spiegel der Seele. Psychosomatische Dermatologie -aktueller Forschungsstand. Z Psychosom Med Psychother 2001; 47: 307-331.
58. Hägermark Ö, Wahlgren CF. Treatment of itch. Semin Dermatol 1995; 14: 320-325.
59. Fleischer AB. The clinical management of itching, Parthenon Publishing Group, New York, 2000: 159-160.
60. Layton AM, Cotterill JA. Notalgia paraesthetica - report of three cases and their treatment. Clin Exp Dermatol 1991; 16: 197-198.
61. Bowling J, Cork MJ. Severe pruritus in a patient with urticaria pigmentosa treated with topical 5 % urea and 3 % polidocanol cream. J Dermatolog Treat 2003; 14: 190-191.
62. Zhai H, Frisch S, Pelosi A, Neibart S, Maibach HI. Antipruritic and thermal sensation effects of hydrocortisone creams in human skin. Skin Pharmacol Appl Skin Physiol 2000; 13: 352-357.
63. Ortonne JP. Skin atrophogenic potential of methylprednisolone aceponate. J Eur Acad Dermatol Venereol 1994; 3 (suppl 1): 13-18.
64. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148: 1212-1221.
65. Wallengren J, Klinker M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol 1995; 32: 287-289.
66. Ständer S, Metze D. Treatment of pruritic skin diseases with topical capsaicin. In: Yosipovitch G, Greaves MW Fleischer AB, McGlone F: Itch: Basic mechanisms and therapy. New York: Marcel Dekker, 2004: 287-304.
67. Reimann S, Luger T, Metze D. Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz. Hautarzt 2000; 51: 164-172.
68. Ständer S, Luger TA. Antipruritische Wirkung von Pimecrolimus und Tacrolimus. Hautarzt 2003; 54: 413-417.
69. Cherill R, Tofte S, MacNaul R, Maher T, Graeber M, Meyer K, Hanifin J. SDZ ASM 981 1 % cream is effective in the treatment of chronic irritant hand dermatitis. J Eur Acad Dermatol Venereol 2000; 14 (suppl 1): 128.
70. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001; 44: 995-998.
71. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol 2001; 137: 1202-1206.
72. Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003; 102: 283-288.
73. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003; 52: 238-245.
74. Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol 2001; 45: 910-913.
75. Thomsen JS, Benfeldt E, Jensen SB, Serup J, Menne T. Topically applied aspirin decreases histamine-induced wheal and flare reactions in normal and SLS-inflamed skin, but does not decrease itch. A randomized, double-blind and placebo-controlled human study. Acta Derm Venereol 2002; 82: 30-35.
76. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol 1994; 31: 613-616.
77. Drake LA, Millikan LE. The antipruritic effect of 5 % Doxepin cream in patients with eczematous dermatitis. Arch Dermatol 1995; 131: 1403-1408.
78. Greenberg JH. Allergic contact dermatitis from topical doxepin. Contact Dermatitis 1995; 33: 281.
79. Shelley WB, Shelley ED, Talanin NY. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996; 34: 143-144.
80. Krause L, Shuster S. Mechanism of action of antipruritic drugs. Br Med J (Clin Res Ed) 1983; 287: 1199-1200.
81. Aubia J, Aguilera J, Llorach I, Garcia C, Rius E, Lloveras J, Masramon J, Llorach M. Dialysis pruritus: effect of cimetidine. J Dial 1980; 4: 141-145.
82. Weisshaar E, Dunker N, Röhl FW, Gollnick H. Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. Exp Dermatol 2004; 13: 298-304.
83. Nykamp D. Comparison of H1-antihistamines for pruritus in end-stage renal disease. Drug Intell Clin Pharm 1986; 20: 806-807.
84. Kanai H, Nagashima A, Hirakata E, Hirakata H, Okuda S, Fujimi S, Fujishima M. The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialysis patients. Life Sci 1995; 57: 207-213.
85. Matsui C, Ida M, Hamada M. Morohashi M, Hasegawa M. Effects of azelastin on pruritus and plasma histamine levels in hemodialysis patients. Int J Dermatol 1994; 33: 868-871.
86. Andoh T, Kuraishi Y. Inhibitory effects of azelastine on substance P-induced itch-associated response in mice. Eur J Pharmacol 2002; 436: 235-239.
87. Francos GC, Kauh YC, Gittlen SD, Schulman ES, Besarab A, Goyal S, Burke JF Jr. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991; 30: 884-889.
88. Dimkovic N, Djukanovic L, Radmilovic A, Bojic P, Juloski T: Uremic pruritus and skin mast cells. Nephron 1992; 61: 5-9.
89. Brune A, Metze D, Luger TA, Ständer S. Antipruritische Therapie mit dem oralen Opiatrezeptorantagonisten Naltrexon: offene, nicht- placebokontrollierte Anwendung bei 133 Patienten. Hautarzt 2004; 55: 1130-1136.
90. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123: 161-167.
91. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115: 1366-1367.
92. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27: 679-684.
93. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41: 431-434.
94. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264-1269.
95. Peer G, Kivity S, Agami O, Firemen E, Silverberg D, Blum M, Iaina A. Randomised crossover trial of naltrexone in uremic pruritus. Lancet 1996; 348: 1552-1554.
96. Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlman U, Mettang T. Naltrexone does not relieve uremic pruritus: results of a randomized, double blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11: 514-519.
97. Ständer S, Metze D. Treatment of pruritus in internal and dermatological diseases with opioid receptor antagonists. In: Yosipovitch G, Greaves MW Fleischer AB, McGlone F: Itch: Basic mechanisms and therapy. New York : Marcel Dekker, 2004: 259-277.
98. Szepietowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med Hypotheses 2002; 58: 176-170.
99. Saltzer EJ, Grove G. Relief from uremic pruritus: a therapeutic approach. Cutis 1975; 16: 298-299.
100. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 1977; 297: 136-138.
101. Gilchrest BA, Rowe JW, Brown RS, Steinman TI, Arndt KA. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979; 91: 17-21.
102. Lazrak S, Skali H, Benchikhi H, Lakhdar H, Fatihi M, Ramdani B, Zaid D. [Phototherapy and hemodialysis pruritus.] Nephrologie 2004; 25: 293-295.
103. Berne B, Vahlquist A, Fischer T, Danielson BG, Berne C. UV treatment of uraemic pruritus reduces the vitamin A content of the skin. Eur J Clin Invest 1984; 14: 203-206.
104. Taylor R, Taylor AE, Diffey BL, Hindson TC. A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron 1983; 33: 14-16.
105. Baldo A, Sammarco E, Plaitano R, Martinelli V, Monfrecola G. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002; 147: 979-981.
106. Lim HW, Vallurupalli S, Meola T, Soter NA. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol 1997; 37: 414-417.
107. Kaptanoglu AF, Oskay T. Ultraviolet B treatment for pruritus in Hodgkin's lymphoma. J Eur Acad Dermatol Venereol 2003; 17: 489-490.
108. Reed J, George S. Pruritic folliculitis of pregnancy treated with narrowband (TL-01) ultraviolet B phototherapy. Br J Dermatol 1999; 141: 177-179.
109. Yashar SS, Gielczyk R, Scherschun L, Lim HW. Narrow-band ultraviolet B treatment for vitiligo, pruritus, and inflammatory dermatoses. Photodermatol Photoimmunol Photomed 2003; 19: 164-168.
110. Karvonen J, Hannuksela M. Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo. Acta Derm Venereol Suppl (Stockh) 1985; 120: 53-55.
111. Väätäinen N, Hannuksela M, Karvonen J. Local photochemotherapy in nodular prurigo. Acta Derm Venereol 1979; 59: 544-547.
112. Jahn S, von Kobyletzki G, Behrens S, Röchling A, Altmeyer P, Kerscher M. Erfolgreiche Behandlung des aquagenen Pruritus mit PUVA-Bad-Photochemotherapie. Z Hautkr 1997; 72: 821-824.
113. Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, Sanchez-Pedreno P, Aliaga A. Treatment of aquagenic urticaria with PUVA and astemizole. J Am Acad Dermatol 1997; 36: 118-119.
114. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31: 1607-1614.
115. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34: 1401-1407.
116. Carruci JA, Washenik K, Weinstein A, Shupack J, Cohen DE. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998; 134: 785-786.
117. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999; 83: 548-552.
118. Zabawski EJ Jr, Kahn MA, Gregg LJ. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999; 5: 10.
119. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-104.
120. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 2003; 42: 491-495.
121. Winhoven SM, Coulson IH, Bottomley WW. Brachioradial pruritus: response to treatment with gabapentin. Br J Dermatol 2004; 150: 786-787.
122. Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999; 13: 227-228.
123. Schürmeyer-Horst F, Fischbach R, Nabavi D, Metze D, Ständer S. Brachioradialer Pruritus: eine seltene, lokalisierte, neuropathische Juckreizform. Hautarzt 2005, Epub ahead of print.
124. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19: 3137-3139.
125. Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998; 16: 121-124.
126. Biondi M, Arcangeli T, Petrucci RM. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom 2000; 69: 165-166.
127. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002; 99: 2627.
128. Zylicz Z, Krajnik M, van Sorge AA, Constantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003; 26: 1105-1112.
129. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10 (Suppl. 4): 19-23.
130. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manage 2003; 25: 288-291.
131. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother 1997; 31: 633-635.
132. Smith KJ, Skelton HG, Yeager J, Lee RB, Wagner KF. Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology 1997; 195: 353-358.
133. Schwörer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993; 341: 1277.
134. Schwörer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Investig 1993; 71: 659-662.
135. Schwörer H, Hartmann H, Ramadori G: Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61: 33-37.
136. Raderer M, Müller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994; 330: 1540.
137. Andrews PA, Quan V, Ogg CS. Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 1995; 10: 140.
138. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999; 354: 397.
139. Albares MP, Betlloch I, Guijarro J, Vergara G, Pascual JC, Botella R. Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. Br J Dermatol 2003; 148: 376-377.
140. Müller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, Raderer M, Scheithauer W, Ferenci P. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10: 865-870.
141. O'Donohue JW, Haigh C, Williams R. Ondansetron in the treatment of cholestasis: a randomised controlled trial. Gastroenterology 1997; 112: A1349.
142. Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996; 16: 958-960.
143. Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. Anesthesiology 1999; 90: 432-436.
144. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001; 18: 346-357.
145. Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 1998; 78: 395-402.
146. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystyn H. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000; 35: 827-831.
147. Murphy M, Reaich D, Pai P, Finns P, Carmichael AJ. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003; 148: 314-317.
148. Londono F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973; 12: 326-328.
149. Calnan CD, Meara RH. Actinic prurigo (Hutchinson's summer prurigo). Clin Exp Dermatol 1977; 2: 365-372.
150. van den Broek H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980; 116: 571-572.
151. Sheskin J. Zur Therapie der Prurigo nodularis Hyde mit Thalidomid. Hautarzt 1975; 26: 215-217.
152. Winkelmann RK, Connolly SM, Doyle JA, Padilha-Goncalves A. Thalidomide treatment of prurigo nodularis. Acta Derm Venereol 1984; 64: 412-417.
153. Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol 2004; 140: 845-849.
154. Silva SR, Viana PC, Lugon NV, Hoette M, Ruzany F, Lugon JR: Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994; 67: 270-273.
155. Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol 2000; 80: 24-25.
156. McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol 1994; 21: 496-499.
157. Rosenbaum MS, Ayllon T. The behavioral treatment of neurodermatitis through habit-reversal. Behav Res Ther 1981; 19: 313-318.
158. Stangier U, Gieler U, Ehlers A. Neurodermitis bewältigen: Verhaltenstherapie, dermatologische Schulung, autogenes Training, Springer-Verlag, Berlin, 1996.
159. Niebel G. Verhaltensmedizin der chronischen Hautkrankheit - Interdisziplinäre Perspektiven der atopischen Dermatitis und ihrer Behandlung, 1. Auflage, Huber, Bern, 1995.
160. Gieler U, Kupfer J, Niemeier V, Brosig B, Stangier U. Atopic eczema prevention programs - a new therapeutic concept for secondary prevention. Dermatol Psychosom 2000; 1: 138-147.
161. Stangier U, Ehlers A, Gieler U. Predicting long-term outcome in group treatment of atopic dermatitis. Psychother Psychosom 2004; 73: 293-301.
162. Staab D, von Rueden U, Kehrt R, Erhart M, Wenninger K, Kamtsiuris P, Wahn U. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol 2002; 13: 84-90.
163. Diepgen TL, Fartasch M, Ring J, Scheewe S, Staab D, Szcepanski R, Werfel T, Wahn U, Gieler U. Neurodermitisschulung. Konzept und aktueller Stand der German Randomized Intervention Multizentre Study. Hautarzt 2003; 54: 946-951.
164. Hoegl L, Fichter M, Plewig G. Stationäre Verhaltensmedizin bei chronischen Hautkrankheiten. Hautarzt 1998; 49: 270-275.
165. Lange S, Zschocke I, Langhardt S, Amon U, Augustin M. Effekte kombinierter therapeutischer Maßnahmen bei Patienten mit Psoriasis und atopischer Dermatitis. Hautarzt 1999; 50: 791-797.
166. Gupta MA. Evaluation and treatment of "psychogenic" pruritus and self-excoriation. J Am Acad Dermatol 1995; 32: 532-533.
167. Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15: 351-359.
168. Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectr 2002; 7: 453-460.
169. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969-973.
170. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 2001; 137: 280-284.
171. Oaklander AL, Bowsher D, Galer B, Haanpää M, Jensen MP. Herpes zoster itch: preliminary epidemiologic data. J Pain 2003; 4: 338-343.
172. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus - new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17: 1558-1563.
173. Black MM, McKay M, Braude PR. Dermatologie in Gynäkologie und Geburtshilfe, Ullstein Mosby, Berlin Wiesbaden, 1997.
174. Roger D, Vaillant L, Fignon A, Pierre F, Bacq Y, Brechet JF, Grangeponte MC, Lorette G. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. Arch Dermatol 1994; 130: 734-739.
175. Bernhard JD. Itch: Mechanisms and management of pruritus, McGraw Hill, New York, 1994.
176. Breneman DL, Cardone JS, Blumsack RF, Lather RM, Searle EA, Pollack VE. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26: 91-94.
177. Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus. A double-blind, placebo-controlled, crossover study of capsaicin 0.025 % cream. Nephron 1996; 72: 617-622.
178. Pauli-Magnus C, Klumpp S, Alscher DM, Kuhlmann U, Mettang T. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 2000; 20: 802-803.
179. De Marchi S, Cecchin E, Villalta D, Sepiacci G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992; 326: 969-974.
180. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004; 19: 1895-1901.
181. Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 643-655.
182. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 1053-1060.
183. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94: 488-493.
184. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264-1269.
185. Terg R, Coronel E, Sordá J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002: 37: 717-722.
186. Borgeat A, Wilder-Smith O, Mentha G, Huber O. Propofol and cholestatic pruritus. Am J Gastroenterol 1992; 87: 672-674.
187. Fleischer AB. The clinical management of itching, Parthenon Publishing, New York London, 2000.
188. Raiford DS. Pruritus of chronic cholestasis. QJM 1995; 88: 603-607.
189. Walt RP, Daneshmend TK, Fellows IW, Taghill PJ. Effect of stanozolol on itching in primary biliary cirrhosis. Br Med J (Clin Res Ed) 1988; 296: 607.
190. Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001; 96: 1563-1570.
191. Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002, 11: 12-24.
192. Shelley WB, Shelley ED. Aquadynia: noradrenergic pain induced by bathing and responsive to clonidine. J Am Acad Dermatol 1998; 38: 357-358.
193. Wolf R, Krakowski A. Variations in aquagenic pruritus and treatment alternatives. J Am Acad Dermatol 1988; 18: 1081-1083.
194. Steinman HK, Greaves MW. Aquagenic pruritus. J Am Acad Dermatol 1985; 13: 91-96.